Ginkgo Bioworks Holdings Inc (NYSE:DNA) Chief Financial Officer Steven P. Coen completed a sale of 33,171 shares of Class A Common Stock on April 13 at $6.414 per share, producing gross proceeds of $212,758. Company filings indicate the disposition was executed to satisfy tax obligations arising from the vesting of performance-based restricted stock units (PSUs).
The transaction follows another set of equity actions by Coen earlier in April. On April 10 he exercised options that resulted in the acquisition of two separate blocks of Class A Common Stock - 28,368 shares and 45,553 shares - which were obtained through the vesting of PSUs.
Ginkgo’s stock has been volatile in recent months. Shares sit at $7.72 as of the most recent quote, which is above the price at which Coen sold on April 13 but still reflects a 53% decline over the past six months.
Company financial and operational developments
In its fourth-quarter 2025 earnings report, Ginkgo flagged improvements in cash management and described ongoing operational restructuring. While the firm’s cell engineering segment saw a revenue decline, management said aggressive cost reductions contributed to a material decrease in operating losses and cash burn.
Concurrently, Ginkgo announced the Ginkgo Cloud Lab, a web-based platform that provides remote access to the company’s automated laboratory infrastructure. The Cloud Lab leverages Reconfigurable Automation Carts (RACs) and offers users connection to more than 70 instruments across a range of biological workflows.
Analyst moves and automation ramp plans
BTIG adjusted its price target for Ginkgo to $5.00 from $9.00 while keeping a Sell rating. Analyst Mark A. Massaro cited the company’s emphasis on building Autonomous Labs by 2026 as a consideration in the revised target.
On the automation front, Ginkgo plans to expand RAC cart automation at its Boston facility from 50 systems to 100 systems by the end of 2026.
Market perspectives and research access
Investor-oriented research referenced in filings notes InvestingPro analysis, which characterizes the stock as appearing undervalued at current levels. DNA’s Pro Research Report is listed among more than 1,400 available reports intended to synthesize company data into actionable insights.
Collectively, the insider sale to cover tax obligations, the company’s recent earnings and restructuring details, the Cloud Lab launch, analyst revisions, and automation expansion plans reflect an active period for Ginkgo as it adjusts operations and financial management.